Market update

Core Viewpoint - EUROAPI's main shareholders, Sanofi and EPIC Bpifrance, have agreed to extend their lock-up period until December 18, 2026, enhancing the stability of EUROAPI's shareholding structure during the execution of its FOCUS-27 plan [1] Business Update - The execution of the FOCUS-27 plan is progressing well, with ongoing improvements in cost efficiency across the organization [1] - EUROAPI anticipates a mid-single digit decrease in Full Year 2025 Net Sales on a comparable basis, a revision from the previously communicated low-single digit decline [5] - The Core EBITDA margin objective for Full Year 2025 remains within the 7% to 9% range due to effective cost reduction measures [5] - A further update will be provided on March 3, 2026, alongside the Full Year 2025 Results [1][5] Company Overview - EUROAPI focuses on reinventing active ingredient solutions to meet global customer and patient needs, with approximately 200 products in its portfolio [2] - The company operates five manufacturing sites in Europe and serves customers in over 80 countries [3] - EUROAPI is listed on Euronext Paris under the ticker EAPI [3]